Finally, experimental validation, including western blot, was conducted to verify the active substance basis of the hepatic disease protection of Cichorium intybus L. In silico analysis and experimental validation together demonstrated that selected compound 13 in Cichorium intybus L. targeted RAC-α serine/threonine-protein kinase (Akt-1) and caspase-1 in hepatocytes, while compound 10 targeted Akt-1. Here, AKT1 is linked to liver disorder.